New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More
Last Close
Oct 21  •  11:43AM ET
9.90
Dollar change
+0.91
Percentage change
10.12
%
Index- P/E- EPS (ttm)-8.49 Insider Own0.03% Shs Outstand0.93M Perf Week16.20%
Market Cap9.21M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.93M Perf Month10.12%
Enterprise Value6.37M PEG- EPS next Q- Inst Own0.04% Short Float0.44% Perf Quarter9.98%
Income-7.01M P/S48.46 EPS this Y- Inst Trans-92.72% Short Ratio0.12 Perf Half Y30.09%
Sales0.19M P/B1.01 EPS next Y- ROA-55.02% Short Interest0.00M Perf YTD41.43%
Book/sh9.76 P/C3.19 EPS next 5Y- ROE-61.65% 52W High12.05 -17.84% Perf Year-12.47%
Cash/sh3.11 P/FCF- EPS past 3/5Y- - ROIC-77.08% 52W Low6.51 52.07% Perf 3Y-56.58%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-47.46% -30.40% Gross Margin- Volatility11.72% 8.16% Perf 5Y-92.97%
Dividend TTM- EV/Sales33.51 EPS Y/Y TTM-293.92% Oper. Margin-1450.89% ATR (14)0.96 Perf 10Y-
Dividend Ex-Date- Quick Ratio2.30 Sales Y/Y TTM-80.31% Profit Margin-3647.11% RSI (14)54.53 Recom4.50
Dividend Gr. 3/5Y- - Current Ratio2.30 EPS Q/Q-126.17% SMA208.14% Beta1.38 Target Price22.87
Payout0.00% Debt/Eq0.01 Sales Q/Q-65.45% SMA5012.68% Rel Volume0.52 Prev Close8.99
Employees2 LT Debt/Eq0.00 EarningsOct 01 BMO SMA20020.93% Avg Volume35.46K Price9.90
IPOJan 29, 2020 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume7,027 Change10.12%
Date Action Analyst Rating Change Price Target Change
Jul-31-24Upgrade H.C. Wainwright Neutral → Buy $30
Oct-01-25 05:01PM
Jun-30-25 01:00AM
Jun-25-25 01:00AM
Jun-19-25 01:00AM
Jun-18-25 01:00AM
01:00AM Loading…
Jun-06-25 01:00AM
Jun-05-25 01:00AM
Jun-03-25 01:00AM
May-12-25 01:00AM
Apr-30-25 01:00AM
Apr-25-25 04:40PM
01:00AM
Apr-24-25 01:00AM
Apr-17-25 01:00AM
Jan-08-25 01:00AM
01:00AM Loading…
Nov-22-24 01:00AM
Nov-11-24 01:00AM
Sep-30-24 01:00AM
Sep-19-24 01:00AM
Sep-04-24 01:00AM
Aug-27-24 01:00AM
Jul-22-24 01:00AM
Jul-15-24 01:00AM
Jul-12-24 01:00AM
Jul-01-24 01:00AM
Jun-06-24 07:52AM
01:00AM
Jun-05-24 01:00AM
May-31-24 01:00AM
May-08-24 01:00AM
07:28AM Loading…
May-06-24 07:28AM
Apr-30-24 07:31AM
Apr-29-24 07:33AM
01:00AM
Apr-19-24 01:00AM
Apr-18-24 06:52AM
01:00AM
Apr-11-24 01:00AM
Apr-03-24 01:00AM
Mar-14-24 02:00AM
Jan-31-24 01:00AM
Jan-09-24 01:00AM
Jan-05-24 01:30AM
Dec-20-23 01:00AM
Dec-14-23 01:00AM
Nov-29-23 01:21AM
01:00AM
Nov-28-23 01:00AM
Nov-23-23 01:00AM
Nov-14-23 01:00AM
Nov-08-23 01:00AM
Nov-02-23 02:00AM
Oct-20-23 01:00AM
Oct-06-23 04:00PM
Oct-05-23 11:20AM
Sep-20-23 01:00AM
Sep-06-23 01:00AM
Sep-05-23 01:00AM
Sep-04-23 01:00AM
Aug-10-23 01:00AM
Aug-04-23 01:00AM
Aug-03-23 01:00AM
Jul-24-23 01:00AM
Jun-15-23 01:00AM
Jun-01-23 01:00AM
May-18-23 01:00AM
May-11-23 01:00AM
May-10-23 01:00AM
May-05-23 01:00AM
May-04-23 01:00AM
Apr-05-23 01:00AM
Apr-04-23 01:00AM
Apr-03-23 01:00AM
Mar-30-23 01:00AM
Mar-28-23 01:00AM
Mar-16-23 02:00AM
Feb-09-23 01:00AM
Feb-06-23 01:00AM
Jan-19-23 01:00AM
Dec-08-22 01:00AM
Nov-11-22 01:00AM
Nov-03-22 02:00AM
02:00AM
Nov-01-22 02:00AM
Sep-20-22 01:00AM
Aug-18-22 01:00AM
Aug-15-22 01:00AM
Aug-12-22 01:00AM
Jul-26-22 04:00PM
Jul-22-22 01:00AM
Jul-21-22 01:00AM
01:00AM
Jun-17-22 01:00AM
May-27-22 01:00AM
May-19-22 01:00AM
May-13-22 01:00AM
May-10-22 01:00AM
May-05-22 01:00AM
Apr-28-22 01:00AM
Apr-25-22 01:00AM
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.